Driving clinical development and speeding time to market through effective relationship management will be two of the key themes discussed at Pharma IQ's 2nd Annual Global Clinical Outsourcing Forum this May.
A recent survey carried out by Pharma IQ revealed some telling stats about the current market activities; 67% of pharmaceutical and biotechnology companies outsource more than HALF of all clinical trials.
However, the risks involved cannot be ignored; with inefficiencies leading to 70% of all trials failing to complete on time, costing manufacturers $1.1m in daily prescription revenues.
Last year, a report by the Association of Clinical Research Organisations (ARCO) into overseas clinical trials found that CROs have taken steps to ensure that both quality and ethical standards are the same in all countries in which they operate, and now a further study is in the pipeline.
FDA Officials have backed up this view by indicating that they would be "tightening regulations for pharmaceutical companies that outsource manufacturing to emerging markets to enhance the safety of products."
This is also highlighted by survey results revealing the perceived biggest obstacles to outsourcing:
1) Establishing CRO accountability 2) Running trials in emerging markets 3) Entering into risk sharing partnerships
Croatian sea fennel may contain a treasure trove of preservative and anti-aging metabolites